Drugs / BLEX 404
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02802423 | Jan 2027 → Apr 2028 expected | triple-negative breast carcinoma | BioLite, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05764928 | Dec 2026 → Dec 2027 expected | non-small cell lung carcinoma | Rgene Corporation | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02944955 | Jan 2027 → Dec 2028 expected | myelodysplastic syndrome | BioLite, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03301805 | Jul 2026 → Apr 2027 expected | malignant pancreatic neoplasm | Rgene Corporation | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLEX 404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05764928 ↗ |
| Action | Activate | “exerted by enhancing the immune system through activation of macrophages, T cells, and natural killer (NK) cells” NCT05764928 ↗ |
| Route | Oral | “BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period.” NCT02802423 ↗ |